Current methods for sentinel lymph node (SLN) mapping and nodal treatment in lung cancer remain inadequate for routine clinical use. Here we discuss the potential for using the combination of invisible near-infrared (NIR) fluorescent light and nanotechnology for these applications. NIR fluorescence imaging has recently received significant attention for in vivo imaging applications because of its low tissue autofluorescence, high photon penetration into living tissue, and high signal-to-background ratio. Our large animal in vivo studies have been able to successfully identify sentinel lymph nodes in lung tissue and several clinical studies have examined the use of NIR fluorescence imaging systems for SLN mapping in breast and gastric cancer. Promising new nanoparticle technologies, when combined with NIR fluorescence imaging, offer the potential for image-guided treatment of lymph nodes at high risk for tumor recurrence. This review provides a theoretical and empirical framework for developing the next-generation of diagnostic and therapeutic agents for lung cancer.
hilar structures and aberrant patterns of lymphatic drainage make detection more difficult (8) (9) (10) (11) . Although Nomori et al. have reported an 83% nodal identification rate following a preoperative injection of technetium-99 colloid, there is an associated increased risk of pneumothorax and bleeding with this method (8) . Further, the recently completed CALGB 140203 multicenter Phase 2 trial investigating the use of intraoperative technetium-99m colloid found an identification rate of only 51% with this technique (9) . Clearly a technology with greater accuracy, improved SBR, and less potential risk to surgeon and patient would be welcome in the field of thoracic oncology. Near-infrared (NIR) fluorescence imaging has the potential to meet this difficult challenge.
Near-Infrared Light
NIR light is defined as that within the wavelength range of 700 to 1000 nm. Although NIR light is invisible to the naked eye, it can be thought of as "redder" than UV and visible light ( Figure 1) . Absorption, scatter, and autofluorescence are all significantly reduced at redder wavelengths. For example, hemoglobin and water are the major photon absorbers in living tissues. The highest absorption coefficient for hemoglobin is present within visible wavelengths and for water is present within UV and infrared wavelengths ( Figure 2 ). In contrast, hemoglobin, water, lipids, and other endogenous chromophores, such as melanin, have their lowest absorption within the NIR spectrum, which permits increased photon depth penetration into tissues (12) (13) (14) (15) (16) . In addition, imaging can also be affected by photon scatter, which describes the reflection and/or deflection of light when it interacts with tissue. Scatter, on an absolute scale, is often ten-times higher than absorption. However, the two major types of scatter, Mie and Rayleigh, are both reduced in the NIR, making the use of NIR wavelengths especially important for the reduction of photon attenuation.
Lastly, living tissue has extremely high "autofluorescence" in the UV and visible wavelength ranges due to endogenous fluorophores, such as NADH and the porphyrins. Therefore, UV/visible fluorescence imaging of the intestines, bladder, and gallbladder is essentially precluded. However, in the NIR spectrum, autofluorescence is extremely low (13, 14) , providing the black imaging background necessary for optimal detection of a NIR fluorophore within the surgical field. As a result of these three special properties, NIR light has received considerable attention in biomedical imaging applications including intraoperative real-time image-guided surgery (13, 14, (17) (18) (19) .
Additionally, optical imaging techniques, such as NIR fluorescence, eliminate the need for ionizing radiation. This, combined with the availability of a NIR fluorophore already FDAapproved for other indications and having extremely low toxicity (discussed below), make this a potentially safe imaging modality. To summarize, the properties of NIR light and NIR fluorescence help to optimize the SBR of SLN detection and permit real-time imaging without the use of ionizing radiation (Box 1).
NIR Fluorescence Imaging Systems
Although NIR light has significant advantages for image-guided surgery, it is also invisible to the human eye. On one hand, this is a major advantage, because there is no change in the appearance of the surgical field. On the other hand, special imaging systems are required to "see" the NIR fluorescent light that is present. Currently there are three intraoperative NIR imaging systems in various stages of development. The Spy ™ system from Novadaq utilizes laser light excitation in order to obtain fluorescent images. The Spy ™ system has been studied for imaging patency of vascular anastamoses following CABG and organ transplantation (20, 21) . A second system, the Photodynamic Eye ™ (PDE) from Hamamatsu is presently available only in Japan. A third system, the Fluorescence-Assisted Resection and Exploration (FLARE ™ ) system developed by our laboratory utilizes NIR light-emitting diode (LED) excitation, eliminating the need for a potentially harmful laser. Additionally, the FLARE ™ system has the advantage of being able to provide simultaneous color imaging, NIR fluorescence imaging, and color-NIR merged images, allowing the surgeon to simultaneously visualize invisible NIR fluorescence images within the context of surgical anatomy. FLARE ™ is completely self-contained, has a working distance of 18″ above the patient, which means there is no need for patient contact, and has a sterile drape and shield to maintain sterility (Figure 3 ). Further details of the FLARE ™ system have been described in detail previously (22, 23) .
Near-Infrared Fluorescent Nanoparticle Contrast Agents
The ideal contrast agent for SLN mapping would be anionic and within 10-50 nm in size in order to facilitate rapid uptake into lymphatic vessels with optimal retention within the SLN (24) (25) (26) . Due to the lack of endogenous NIR tissue fluorescence, exogenous contrast agents must be administered for in vivo studies. The most important contrast agents that emit within the NIR spectrum are the heptamethine cyanines fluorophores, of which indocyanine green (ICG, Figure 4 ) is the most widely used, and fluorescent semiconductor nanocrystals, also known as quantum dots (QDs).
ICG is an extremely safe NIR fluorophore, with its only known toxicity being rare anaphylaxis. The dye was FDA approved in 1958 for systemic administration for indicatordilution studies including measurements of cardiac output and hepatic function. Additionally, it is commonly used in ophthalmic angiography. When given intravenously, ICG is rapidly bound to plasma albumin and cleared from the blood via the biliary system. Peak absorption and emission of ICG occur at 780 nm and 830 nm respectively, within the window where in vivo tissue absorption is at its minimum (17) . ICG has a relatively neutral charge, has a hydrodynamic diameter of only 1.2 nm, and is relatively hydrophobic. Unfortunately, this results in rapid transport out of the SLN and relatively low fluorescence yield, thereby decreasing its efficacy in mapping techniques. However, noncovalent adsorption of ICG to human serum albumin (HSA), as occurs within plasma, results in an anionic nanoparticle with a diameter of 7.3 nm and a three-fold increase in fluorescence yield markedly improving its utility in SLN mapping (26) .
QDs consist of an inorganic heavy metal core and shell which emit within the NIR spectrum. This structure is then surrounded by a hydrophilic organic coating which facilitates aqeuous solubility and lymphatic distrubtion. QDs have been extensively studied and are ideal for SLN mapping as their hydrodynamic diameter can be customized to the appropriate size within a narrow distribution (15-20 nm), they can be engineered to have an anionic surface charge, and exhibit an extremely high SBRs with significant photostability (15, 27) . Unfortunately, safety concerns due to the presence of heavy metals within the QDs so far have precluded clinical application (28).
Preclinical Animal Studies
As a proof of concept for intrathoracic SLN mapping, our lab has previously investigated the use of QDs and ICG:HSA for SLN mapping of the pleural space, lung, and esophagus with great success (29) (30) (31) . NIR QDs have been injected into the pleural space, lung, or esophagus of both rats and pigs with good result. Animals were imaged after injection of the NIR contrast agent within the lung parenchyma using the FLARE ™ NIR fluorescence imaging platform and SLN(s) was identified. In all 16/16 experiments in pigs the SLN was identified within 5 minutes of injection ( Figure 5 ), 14 of which were located in the ipsilateral mediastinum and 2 of which were hilar intraparenchymal nodes (29) . In a similar experiment 16 rats and 6 pigs were injected with QDs into the pleural space, following which the SLN was identified in the superior mediastinum in all cases (30) 31) . Further large animal studies of NIR SLN mapping with QDs have been conducted in several large animal organ systems, including skin, stomach, colon, and bladder, providing further validation of this system (27, (32) (33) (34) (35) (36) . While NIR fluorescent QDs may be ideal for lymphatic mapping given their diameter and anionic charge, they consist of a potentially toxic heavy metal core making them problematic for human use until further toxicology studies are completed (28) .
Given these concerns, several animal studies have investigated the use of indocyanine green for lymphatic imaging (23, 26, (37) (38) (39) (40) . While ICG:HSA may not have the ideal charge or size for lymphatic uptake, it has the advantage of being extremely safe and composed of drugs already FDA-approved for other indications. Of published studies, three have investigated the use of ICG:HSA for sentinel lymph node mapping in large animals (23, 26, 37) . Similar to the previously described QDs, the ICG:HSA formulation reliably identified the draining sentinel node following subcutaneous injections. The clinical relevancy of this powerful approach was demonstrated by the study from Tanaka, et al. in which both QDs and ICG:HSA were tested as lymphatic tracers in a spontaneous melanoma model in Sinclair pigs. Both agents resulted in rapid lymphatic migration from injection sites around melanoma lesions with easy identification of the SLN in 4 of 4 experiments for each (37) . Of great importance was the subsequent identification of micrometastatic disease in the SLN removed under NIR guidance, with absence of disease in non-NIR positive nodes within the same regional basin.
Human Clinical Studies of NIR SLN Mapping
Several studies have investigated the clinical use of indocyanine green without adsorption to HSA for NIR fluorescence-guided SLN mapping in breast and gastric cancer with good success (41-45). Kitai et al. first examined this technique in 2005 in breast cancer patients, and was able to identify a SLN node in 17 of 18 patients using NIR fluorescence rather than the visible green color of ICG (41) . Sevick-Muraca et al. reported similar results using significantly lower microdoses of ICG (10 -100 μg), successfully identifying the SLN in 8 of 9 patients (43). Similar to these subcutaneous studies, 56 patients with gastric cancer underwent endoscopic ICG injection into the submucosa around the tumor 1 to 3 days preoperatively or injection directly into the subserosa intraoperatively with identification of the SLN in 54 patients (45) . Interestingly, this study showed that preoperative injection was associated with identification of a higher number of NIR-positive nodes and a higher accuracy rate compared to intraoperative injection. This suggests that more ICG can migrate further down the lymphatic pathways over time, reaching several draining lymph nodes all at risk for metastatic disease. This is likely the result of the small diameter and hydrophobicity of ICG. For this reason, ICG:HSA may prove to be a more accurate contrast agent for SLN mapping.
Recently, Troyan et al. have completed a pilot phase I clinical trial examining the utility of NIR imaging the ICG:HSA nanoparticle fluorophore for SLN mapping/biopsy in breast cancer using the FLARE ™ system (23) . In this study, 6 patients received both 99m Tc-sulfur colloid lymphoscintigraphy along with ICG:HSA at micromolar doses. SLNs were identified in all patients using both methods. In 4 of 6 patients the SLNs identified were the same, while in the remaining two, lymphoscintigraphy identified an additional node in one patient and ICG:HSA identified an additional SLN in the other. Irrespective, this study demonstrates that NIR SLN mapping with low dose ICG:HSA is a viable method for intraoperative SLN identification.
These promising preclinical and clinical trial results suggest that NIR imaging may provide an easy, reliable method for SLN mapping in lung cancer. For this reason, we have recently begun a phase I clinical trial at Brigham and Women's Hospital to study the utility of such a technique in human NSCLC (Figure 3b ). This study is currently in the early dose-escalation phases and is actively enrolling patients. Given the potential impact of SLN identification in NSCLC, we are eagerly awaiting the results of this trial.
Nanotechnology and Drug Delivery in Lung Cancer
In addition to its uses in molecular imaging, nanotechnology has received much interest for drug delivery. Polymer nanotechnology has been an area of significant research over the past decade as polymer nanoparticle drug delivery systems offer several advantages over traditional methods of chemotherapy delivery. As nanoparticles are easily modified, they can be customized for both the type of drug and target site, thereby increasing specificity of drug delivery while reducing systemic toxicity (46) (47) (48) (49) . As the importance of micrometastatic lymphatic spread of tumor becomes clearer, there has been much interest in the use of nanoparticles for lymphatic drug delivery. The considerable focus on developing an effective method for SLN mapping for lung cancer is indicative of the importance of nodal spread on overall survival. Further, a recent study from Chen, et al. showed approximately 200-fold greater levels of chemotherapy in regional lymph nodes following subcutaneous injection compared with intravenous administration in patients with breast cancer (50) . A method to guide, concentrate, and keep chemotherapy within these regional lymph nodes could have a major impact on survival after resection (51) .
Several investigators have shown delivery of nanoparticles to lymph nodes in small animal systems (52) (53) (54) (55) (56) (57) (58) . A recent study by Liu, et al. has shown the feasibility of translymphatic delivery of paclitaxel to mediastinal lymph nodes following intrapleural implantation of a gelatin sponge impregnated with polylactide-co-glycolide paclitaxel microspheres (57) . Our lab is investigating the use of image-guided nanoparticles engineered for lymphatic drug delivery. We have previously described the synthesis of novel, pH-responsive methacrylate nanoparticle systems (59) . Following a simple subcutaneous injection of NIR fluorophorelabeled nanoparticles 70 nm in size, we have shown that we can deliver paclitaxel loaded within the particles to regional draining lymph nodes in several organ systems of Yorkshire pigs while simultaneously confirming nodal migration using NIR fluorescent light ( Figure  6 ). Future studies will need to investigate the ability of nanoparticles to treat and prevent nodal metastases in animal cancer models. Additionally, the development of tumor specific nanoparticles will potentially allow for targeting of chemotherapy to small groups of metastatic tumor cells further limiting systemic toxicities by narrowing the delivery of cytotoxic drugs (60) .
Summary and Conclusion
Regional lymphatic spread and recurrence of NSCLC remains a significant cause of patient morbidity. SLN mapping is currently the standard of care for several solid organ malignancies. Unfortunately, for various reasons SLN mapping has not been readily adopted for treatment and staging of NSCLC. As an imaging modality ideal for real-time, intraoperative use in vivo, NIR fluorescence imaging has the potential to become a relatively simple and reliable method for SLN mapping. Several studies have validated this technique in human trials in breast and gastric cancer. Our currently active Phase I clinical trial will investigate its clinical efficacy and determine the feasibility of intraoperative NIR SLN mapping in lung cancer.
Finally, nanomedicine is an exciting new field that offers the opportunity to customize and target delivery of chemotherapy to areas of interest. Nanotechnology provides a potential method to deliver chemotherapy via the lymphatic system and isolate drug delivery to regional draining lymph nodes. By avoiding systemic delivery this method may significantly reduce toxicity, while still concentrating chemotherapeutic agents in lymph nodes at levels that cannot be currently achieved. Further, with the future development of tumor specific nanoparticles, drugs may be targeted to small numbers of tumor cells providing a new modality for treatment of, at least regionally, metastatic disease. By combining these two innovative technologies we may one day be able to target both contrast agents and cytotoxic agents to tumor cells that currently evade existing cancer therapies. Between 700 and 900 nm (the "NIR Window"), the sum of the oxygenated hemoglobin (OxyHb), deoxygenated hemoglobin (DeoxyHb), water, and lipid spectra reaches a minimum, thereby helping to make this window ideal for in vivo imaging. FLARE ™ imaging system fully extended, undraped (a) and fully draped, in intra-operative use (b). The camera head is fully enclosed and sits 18 cm above the field of view (arrow). A satellite monitor (arrowhead) is positioned in the operating room to allow for easy viewing by the surgeon. 24 hours following a subcutaneous injection into the hindleg of a Yorkshire pig (arrowhead), NIR labeled methacrylate nanoparticles are seen migrating to the draining SLN (arrow) through a discrete lymphatic vessel. 
